Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 48.00p 47.50p 48.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 97.5 22.2 3.9 12.5 226.90

Alliance Pharma Share Discussion Threads

Showing 1401 to 1424 of 1425 messages
Chat Pages: 57  56  55  54  53  52  51  50  49  48  47  46  Older
DateSubjectAuthorDiscuss
24/4/2017
14:26
Sale of 12 M shares by Aviva - I'm hoping that's what's been holding the share price back. There are 472 M shares in issue and Aviva retain a 5% holding or ~23.6M shares. Means they've sold ~1/3 of their original holding, so quite significant.
pawdaw
20/4/2017
23:52
This is going to pop soon - - north.
krobertson878
20/4/2017
22:28
cumnor: Could be institutional swapses - i.e pre-arranged trades between houses off market.
pugugly
20/4/2017
22:21
TW nothing to do with 21ml volume whatsoever. Something up?
cumnor
20/4/2017
21:51
If TW tipped maybe best to wait a few weeks until short term punters sell to skim a small profit = prices fall back and then stop losses triggered - then maybe possible to consider - Apparently a well managed company though debt moderately high but being worked down. But DYOR etc.
pugugly
20/4/2017
16:36
21m traded??? A tad unusual
craigy
20/4/2017
15:37
10m traded???
craigy
20/4/2017
13:21
Tipped by TW again, which some regards as the Kiss of Death
2vdm
30/3/2017
12:07
DVB99, Thought the same thing, I think it's more the cash generation here that makes the level comfortable than the level itself. Not a concern, but made me smile all the same.
al101uk
30/3/2017
11:59
this made me laugh - "At the year-end, the adjusted net debt/EBITDA ratio was 2.8 times and comfortably below our banking covenant of 3.0 times." COMFORTABLY - really??????????
dvb99
30/3/2017
11:36
http://www.thetimes.co.uk/article/few-signs-of-growth-despite-fall-in-debt-g5k6bn2p8
norbert colon
30/3/2017
07:29
Good buy rec in today's Times BUY
nw99
29/3/2017
14:39
I agree. I think this is a bit under the radar, but definitely a long term hold
2vdm
29/3/2017
13:29
Guess the market is underwhelmed because of debt, gearing at 2.8. However it has reduced by £3m since June with the £5m Sinclair payment to come, so provided we can continue to keep cash rolling in and debt decreasing it's a bargain below 50p IMO.
dozey3
29/3/2017
12:08
Looks good, would have liked a bit more clarification on the compensation from Sinclair, but management seem capable and gains elsewhere in the business appear to be compensating for the issues with Kelo-stretch. In effect the £5 million and the US rights to Flammacerium could be considered a bonus in excess of expectations. Happy to hold and may be tempted to add on any weakness in the new tax year.
al101uk
29/3/2017
11:56
Doubled up here
nw99
29/3/2017
07:46
Excellent set of results and well done to the BOD. share price more than justified imo. Hopefully onwards and upwards.
2vdm
29/3/2017
07:25
Sales and profits have doubled nice
nw99
21/3/2017
12:20
From April 2016: "Since completion of the acquisition in mid-December 2015, sales of Kelo-stretchTM, which had been identified as a key growth brand, have been lower than anticipated despite extensive promotional activities by A. Menarini Asia-Pacific Pte. Ltd., our key partner in South East Asia. Despite this, other Sinclair brands they distribute for us are performing well. The relationship with Menarini remains strong and other opportunities are being positively explored. The 2016 impact of the Kelo-stretch shortfall is estimated at a possible reduction of £1.2m at the operating profit level. Notwithstanding this, trading to date for the Sinclair Healthcare Products in aggregate has remained in line with management's expectations." "The fair value of intangible assets recognised on business combination comprise the following product related intangibles: Aloclair, Atopiclair, Flamma franchise, Kelo-cote, Kelo-stretch, Other Dermatology Products and Other Specialist Hospital Products." Worth keeping an eye on amortisation of intangible assets at results.
al101uk
21/3/2017
07:11
Great news £5m better off this am
nw99
13/3/2017
09:22
Buying ahead of results
nw99
01/3/2017
08:00
I agree with your views re longer term prospects but suspect that as it grows it may become a target for a larger fish.
2vdm
28/2/2017
09:50
I have added on the recent weakness. Held since early 2011 and like the long term prospects and relative stability of the business. I intend for APH to remain in my portfolio for 10yrs +
norbert colon
27/2/2017
16:53
Moderate volume and continuing fall in share price 4 day faller down 9.55% - No news. Could an II be unloading ? Looks as though going nowhere at the moment or could it be those who bought in on the Hardman reseach having stop losses triggered - Any other thoughts / knowledge ?
pugugly
Chat Pages: 57  56  55  54  53  52  51  50  49  48  47  46  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170428 06:14:14